(Society of Nuclear Medicine and Molecular Imaging) In a mouse model, researchers have demonstrated that a novel, affibody-based pretargeted radionuclide therapy for HER2 (human epidermal growth factor receptor 2)-expressing cancers is non-toxic to the kidneys and improves survival. The study is reported in The Journal of Nuclear Medicine's July featured article of the month.
from EurekAlert! - Technology, Engineering and Computer Science https://ift.tt/2NgIwgR
Tuesday, July 3, 2018
Novel pretargeted radionuclide therapy for HER2-expressing cancers shows promise
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment